Peptide News Digest

#France

2 stories

Research · View digest

Ifop Poll: 18% of French Adults Are Interested in Weight-Loss Drugs; Over 40% of Them Would Consider Skipping a Prescription

In an online Ifop survey of 3,004 French adults conducted in May for the news site Darwin Nutrition, 18% said they would be interested in drugs such as Wegovy and Mounjaro, while only 4% had ever taken one, compared with 15% in the U.S., The Connexion reported on November 10. More than 40% of those interested, and 55% of interested 18- to 34-year-olds, said they would consider getting the drugs without a prescription, such as by ordering from abroad or through friends; the drugs are prescription-only in France and partly reimbursed in some cases since June 2026.

Regulatory · View digest

France Joins UK and Switzerland: Wegovy (Semaglutide) and Mounjaro (Tirzepatide) Public Insurance Coverage Live June 15 With 65% Sécurité Sociale Reimbursement

Wegovy and Mounjaro became reimbursable by French Health Insurance effective June 15, 2026 under orders published in the May 28, 2026 Journal Officiel. The patient co-payment rate is 35%, leaving 65% public coverage by the Sécurité Sociale. Eligibility is restricted to specific patient profiles: adults with BMI ≥30 plus a major obesity-associated comorbidity (Wegovy) or with type 2 diabetes (Mounjaro). The decision follows the UK and Switzerland in extending public insurance to GLP-1 obesity therapy, and marks a paradigm shift from 'personal responsibility' toward 'treatable disease' framing in continental European health systems. The change comes ahead of EMA Wegovy pill (oral semaglutide 25 mg) EU launches in H2 2026 following the May 22 CHMP positive opinion.